Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
ImmunoGen, Inc. (IMGN)
ImmunoGen at Morgan Stanley Healthcare Conference
September 12, 2012 08:00 AM ET
Dan Junius, President and CEO
Marshall Urist - Morgan Stanley
Marshall Urist - Morgan Stanley
Previous Statements by IMGN
» ImmunoGen's CEO Discusses F4Q12 Results - Earnings Call Transcript
» ImmunoGen CEO Discusses F1Q11 Results - Earnings Call Transcript
» ImmunoGen, Inc. F4Q10 (Qtr End 06/30/10) Earnings Call Transcript
Sure. Thanks Marshall and thank you for inviting us. Maybe just by the way of background in terms of the company, the technology, and our movement is some of the things that we are involved with. The company is built on a technology that uses the targeting ability of an antibody to find a target on a cancer cell and we’ve developed a technology that has both proprietary toxin that we use and a means of attaching that toxin to the antibody that is delivered for us a very effective targeted therapy for oncology.
We’ve been working on that and we continue to bring new innovations in and where we are with the program at this point, from a strategic standpoint we are in the process of moving to a company that develops proprietary compound. We have (inaudible) in the clinic today. I’ll come back and just provide a brief update on that, but that effort has been somewhat overshadowed by what is taking place in our partner pipeline.
There are 8 compounds in the clinic and two partners, our partner includes Roche, Sanofi, Novartis, Lilly, Bayer and the dominant compound or the most advanced compound in that partner pipeline is T-DM1. T-DM1 gained a compound being advanced by Roche as effectively the replacement for Herceptin. Herceptin, both because of its coming off of patent, but also because of some extraordinary data that has been reported associated with T-DM1 has shown it to be very effective and we’ve seen it thus far in the first line and second line showing a substantially better efficacy while affording the tolerability benefits associated with the targeted therapy that is in place. So, the partner pipeline is developing nicely. T-DM1 will be a lot of news coming out on that and there has been a lot of news to date, but that will continue as they now have the compound submitted for metastatic treatment for patients who failed an earlier line of Herceptin therapy and so we will hear more about that hopefully acceptance and approval by the FDA and European regulators, but they are also looking at an adjuvant. They have a gastric study underway so there is quite a bit taking place there. Behind that on the partner side, there are a number of other compounds that are advancing.
Sanofi has a compound for Non-Hodgkin's lymphoma that is in three phase, two studies. We expect to be hearing more about that, but that it is over the coming quarters. The data thus far has been very good, both in terms of efficacy as well as tolerability and other partners are advancing their compounds. We expect to see some of those compounds moving into pivotal studies over the course of 2013.
So, a lot going on in the partner front. Our newest partner Lilly and Novartis are doing a lot of work pre-clinically. We think that those will lead to compounds coming to the clinic in a reasonable period of time, but back to the proprietary side as for the strategy is to build on the technology base that really has been funded through a lot of partner activity over the years and advance the proprietary pipeline.
Our most advanced proprietary compound is IMGN901 that is in page 2 clinical studies for first line small cell lung cancer in combination with carboplatin and etoposide. Small cell lung cancer we know is a very difficult disease. Patient’s respond to the existing therapy, but with no durability. So, what we are looking for is to be able to extend the durability of a response by adding 901. We had data just to the symposium last week out in Chicago and what that data showed in establishing the phase II dose, it was essentially an all comers study for patients who would be getting a carboplatin etoposide therapy to which we added 901. Most of these patients expressed their target CD56, but what we found was, a) that we could dose 901 at the same level that we dosed it in monotherapy studies, which again speaks to the tolerability of this approach but also that we saw some interesting activity in small cell lung cancer patients, because they were a number of them in the study. A few of them chemo-naïve, many of them platinum-refractory/resistant and we saw some activity there, which can be very difficult in later stage small cell lung cancer patients. So, very encouraged with that. Behind that we have two other compounds that have come into the clinic over the last several months one, for Non-Hodgkin's lymphoma, the target there is CD37. We think while Non-Hodgkin's lymphoma receives a lot of attention, there are a number of therapies there, we think this is a highly differentiated offering because again using our antibody-drug conjugate technology. What we’ve done is we’ve developed an antibody that pre-clinically has shown a high level of activity as a naked agent, to which we have then added our conjugate technology. So, we think that offers tremendous promise and then, the last proprietary compound which really just started dose in few months ago, is one that targets the Folate receptor 1. And we think that it’s an interesting target, over expressed in a variety of cancers. And what we have with that particular compound, in addition to it being an interesting target, we brought forward our fourth unique linker, and each of our linkers conveys a different set of characteristics on the conjugate, this one happens to counter multi-drug resistance which it can common in many cancers and pre-clinically this looked to be a highly efficacious compound. So, we’re excited to see that develop. So that’s kind of a mini update on where we are.